Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients

Vancomycin is commonly added as empiric therapy for febrile neutropenia. A retrospective chart review was conducted at a large community teaching institution to evaluate vancomycin use in oncology patients. The results revealed that a majority of empiric vancomycin therapy was inappropriate, raising...

Descripción completa

Detalles Bibliográficos
Autores principales: Libuit, Jessica, Whitman, Andrew, Wolfe, Rebecca, Washington, Casey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324182/
https://www.ncbi.nlm.nih.gov/pubmed/25734080
http://dx.doi.org/10.1093/ofid/ofu006
_version_ 1782356646820839424
author Libuit, Jessica
Whitman, Andrew
Wolfe, Rebecca
Washington, Casey S.
author_facet Libuit, Jessica
Whitman, Andrew
Wolfe, Rebecca
Washington, Casey S.
author_sort Libuit, Jessica
collection PubMed
description Vancomycin is commonly added as empiric therapy for febrile neutropenia. A retrospective chart review was conducted at a large community teaching institution to evaluate vancomycin use in oncology patients. The results revealed that a majority of empiric vancomycin therapy was inappropriate, raising concern for antibiotic resistance and prompting opportunities for improvement.
format Online
Article
Text
id pubmed-4324182
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43241822015-03-02 Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients Libuit, Jessica Whitman, Andrew Wolfe, Rebecca Washington, Casey S. Open Forum Infect Dis Brief Reports Vancomycin is commonly added as empiric therapy for febrile neutropenia. A retrospective chart review was conducted at a large community teaching institution to evaluate vancomycin use in oncology patients. The results revealed that a majority of empiric vancomycin therapy was inappropriate, raising concern for antibiotic resistance and prompting opportunities for improvement. Oxford University Press 2014-04-10 /pmc/articles/PMC4324182/ /pubmed/25734080 http://dx.doi.org/10.1093/ofid/ofu006 Text en © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Reports
Libuit, Jessica
Whitman, Andrew
Wolfe, Rebecca
Washington, Casey S.
Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title_full Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title_fullStr Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title_full_unstemmed Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title_short Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
title_sort empiric vancomycin use in febrile neutropenic oncology patients
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324182/
https://www.ncbi.nlm.nih.gov/pubmed/25734080
http://dx.doi.org/10.1093/ofid/ofu006
work_keys_str_mv AT libuitjessica empiricvancomycinuseinfebrileneutropeniconcologypatients
AT whitmanandrew empiricvancomycinuseinfebrileneutropeniconcologypatients
AT wolferebecca empiricvancomycinuseinfebrileneutropeniconcologypatients
AT washingtoncaseys empiricvancomycinuseinfebrileneutropeniconcologypatients

Ejemplares similares